Pharmacoeconomic evaluation of schizophrenia in Taiwan: Model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs

Psychiatry and Clinical Neurosciences

Volumn 59, Issue 4, 2005, Pages 385-394

  Yang, Yen Kuang ^a   Tarn, Yeng Hui ^b   Wang, Ting Ying ^c   Liu, Chia Yih ^d   Laio, Yi Cheng ^e   Chou, Yuan Hwa ^f   Lee, Shin Min ^g   Chen, Chun Chih ^e  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b TAIPEI CITY HOSPITAL   (Taiwan)

^c TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^f NATIONAL YANG MING UNIVERSITY   (Taiwan)

^g Department of Health   (Taiwan)

Author keywords

Long acting antipsychotics; Model comparison; Pharmacoeconomic evaluation; Schizophrenia

Indexed keywords

HALOPERIDOL; OLANZAPINE; RISPERIDONE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DATA BASE; DISEASE DURATION; DRUG COST; EXTRAPYRAMIDAL SYMPTOM; HUMAN; KAPLAN MEIER METHOD; NATIONAL HEALTH INSURANCE; PATIENT COMPLIANCE; PSYCHIATRIST; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; TAIWAN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COHORT STUDIES; COST SAVINGS; COSTS AND COST ANALYSIS; DECISION TREES; DELAYED-ACTION PREPARATIONS; DYSKINESIA, DRUG-INDUCED; FEMALE; HOSPITALIZATION; HUMANS; LONG-TERM CARE; MALE; MENTAL HEALTH; MODELS, ECONOMIC; PATIENT COMPLIANCE; PUBLIC HEALTH; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TAIWAN; TREATMENT OUTCOME;

EID: 23744504652     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2005.01390.x     Document Type: Article

References (33)

1. Tarricone R, Gerzeli S, Montanelli R et al. Direct and indirect costs of schizophrenia in community psychiatric services in Italy. The GISIES study. Interdisciplinary study group on the economic impact of schizophrenia. Health Policy 2000; 51: 1-18.
2. Ko SY, Chen PS, Yang YK et al. Correlation between performance on the continuous performance test and economic costs in patients with schizophrenia. Psychiatry Clin. Neurosci. 2003; 57: 373-377.
3. Andrews G, Hall W, Goldstein G et al. The economic costs of schizophrenia. Implications for public policy. Arch. Gen. Psychiatry 1985; 42: 537-543.
4. Wasylenki DA. The cost of schizophrenia. Can. J. Psychiatry 1994; 39: S65-S69.
5. Rund BR, Ruud T. Costs of services for schizophrenic patients in Norway. Acta Psychiatr. Scand. 1999; 99: 120-125.
6. Kelleher JP, Centorrino F, Albert MJ et al. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. CNS Drugs 2002; 16: 249-261.
7. Kane JM, Edrdekens M, Lindenmayer JP et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am. J. Psychiatry 2003; 160: 1125-1132.
8. Fleischhacker WW, Eerdekens M, Karcher K et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J. Clin. Psychiatry 2003; 64: 1250-1257.
9. Bureau of National Health Insurance. National Health Insurance Annual Statistical Report 1999. Bureau of National Health Insurance, Taipei, Taiwan, 2000.
10. Knapp M. Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatri. Scand. 2000; 102: 15-18.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1958; 53: 457-481.
12. Llorca PM, Jasso-Mosqueda JG. Long-acting risperidone injection in patients with schizophrenia compared with oral olanzapine and haloperidol decanoate: Results of a cost-effectiveness model. Poster presented at the 16th Congress of the European College of Neuropsychopharmacology (ECNP), 20-24 September 2003, Prague, Czech Republic.
13. Overall JE, Beller SA. The Brief Psychiatric Rating Scale (BPRS) in geronpsychiatric research: I. Factor structure on an inpatient unit. J. Gerontol. 1983; 9: 187-193.
14. Adams CE, Fenton MK, Quraishi S et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br. J. Psychiatry 2001; 179: 290-299.
15. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur. Neuropsychopharmacol. 2004; 14: 87-92.
16. Rabinowitz J, Lichtenberg P, Kaplan z et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am. J. Psychiatry 2001; 158: 266-269.
17. Andreasen NC. Assessment issues and the cost of schizophrenia. Schizophr. Bull. 1991; 17: 475-481.
18. Chouinard G, Jones B, Remington G et al. A Canadian multi-center placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 1993; 13: 25-40.
19. Chue P, Eerdekens M, Augustyns I. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur. Neuropsychopharmacol. 2005; 15: 111-117.
20. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. J. Clin. Psychopharmacol. 1997; 17: 194-201.
21. Tran PV, Hamilton SH, Kuntz AJ et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J. Clin. Psychopharmacol. 1997; 17: 407-418.
22. Weiden P, Glazer W. Assessment and treatment selection for 'revolving door' inpatients with schizophrenia. Psychiatr. Q. 1997; 68: 377-392.
23. Yang YK, Hsieh HH, Wu AC et al. Help-seeking behaviors in relatives of schizophrenics in Taiwan. Gen. Hosp. Psychiatr 1999; 21: 303-309.
24. Hogarty GE, Ulrich RF. The limitations of antipsychotic medication on schizophrenia relapse and adjustment and the contributions of psychosocial treatment. Psychiatry Res. 1998; 32: 243-250.
25. Knoll JL IV, Garver DL, Ramberg JE et al. Heterogeneity of the psychoses: is there a neurodegenerative psychosis? Schizophr. Bull 1998; 24: 365-379.
26. Liao YC, Yang YK, Chen PS et al. The comparison of extrapyramidal side-effects, cognitive function and economic cost in haloperidol-treated and risperidone-treated in outpatients with chronic schizophrenia: a naturalistic study. Taiwanese J. Psychiatry 2003; 17: 293-301.
27. Tollefson GD, Beasley CM Jr, Tran PV et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am. J. Psychiatry 1997; 154: 457-465.
28. Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000; 17: 383-389.
29. Palmer CS, Revicki DA, Genduso LA et al. A cost-effectiveness clinical decision analysis model for schizophrenia. Am. J. Manag. Care 1998; 4: 345-355.
30. Procyshyn RM, Zerjav S. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine. Clin. Ther. 1998; 20:1203-1217; 1192-3.
31. Del Paggio DSD. The pharmacoeconomics and efficacy of atypical antipsychotics within Alameda County BHCS. Behav. Health Care 1998; 2: 10-14.
32. Linszen D, Birchwood M. The early phase psychosis and schizophrenia a critical period for patients, family and the profession. In: Birchwood M, Fowler D, Jackson C (eds). Early Intervention in Psychosis: A Guide to Concepts, Evidence Interventions. John Wiley and Sons, Chichester, 2000; 261-280.
33. D'Ausilio A, Marconi S, Antonini A et al. Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase. Recenti Prog. Med. 2003; 94: 484-493.